Cellectar Biosciences (Cellectar Biosciences) Cash-to-Debt : 17.30 (As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

What is Cellectar Biosciences Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Cellectar Biosciences's cash to debt ratio for the quarter that ended in Dec. 2023 was 17.30.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Cellectar Biosciences could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Cellectar Biosciences's Cash-to-Debt or its related term are showing as below:

CLRB' s Cash-to-Debt Range Over the Past 10 Years
Min: 11.31 Med: 75.75 Max: 6628
Current: 17.3

During the past 13 years, Cellectar Biosciences's highest Cash to Debt Ratio was 6628.00. The lowest was 11.31. And the median was 75.75.

CLRB's Cash-to-Debt is ranked better than
63.21% of 1541 companies
in the Biotechnology industry
Industry Median: 6.49 vs CLRB: 17.30

Cellectar Biosciences Cash-to-Debt Historical Data

The historical data trend for Cellectar Biosciences's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Cellectar Biosciences Cash-to-Debt Chart

Cellectar Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

20.10

135.46

118.62

32.89

17.30

Cellectar Biosciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															32.89	21.17	8.81	33.37	17.30

Competitive Comparison of Cellectar Biosciences's Cash-to-Debt

For the Biotechnology subindustry, Cellectar Biosciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cellectar Biosciences's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cellectar Biosciences's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Cellectar Biosciences's Cash-to-Debt falls into.

Cellectar Biosciences Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Cellectar Biosciences's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	9.565	/	(0.059	+	0.494)
	=	17.30

Cellectar Biosciences's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	9.565	/	(0.059	+	0.494)
	=	17.30

Cellectar Biosciences (NAS:CLRB) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Cellectar Biosciences Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Cellectar Biosciences's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Cellectar Biosciences (Cellectar Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellectar Biosciences Inc (NAS:CLRB) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

NV4:Germany NV4:Germany

Address

100 Campus Drive, Florham Park, NJ, USA, 07932

Website

https://www.cellectar.com

Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and better safety as a result of fewer off-target effects. Its lead PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.

Executives

Andrei Shustov	officer: Senior Vice President, Medical	7 PARKLAND DRIVE, MILFORD NJ 08848
Darrell Shane Lea	officer: Chief Commercial Officer	7 PARKLAND DRIVE, MILFORD NJ 08848
Chad J Kolean	officer: Chief Financial Officer	C/O CELLECTAR BIOSCIENCES, INC., 3301 AGRICULTURE DRIVE, MADISON WI 53716
Douglas J Swirsky	director	C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD SUITE 455, ROCKVILLE MD 20850
Frederick W Driscoll	director
Asher Chanan-khan	director	C/O CELLECTAR BISCIENCES, INC., 100 CAMPUS DRIVE NJ 07932
James V Caruso	director, officer: President and CEO	C/O CELLECTAR BIOSCIENCES, INC., 8383 GREENWAY BLVD STE 600, MIDDLETON WI 53562
Dov Elefant	officer: Chief Financial Officer	EPICEPT CORPORATION, 270 SYLVAN AVENUE, ENGLEWOOD CLIFFS NJ 07632
Jarrod Longcor	officer: Chief Business Officer	C/O RIB-X PHARMACEUTICALS, INC., 300 GEORGE STREET, SUITE 301, NEW HAVEN CT 06511
Friend John E. Ii	officer: VP, Chief Medical Officer	26 ORCHARD LANE, COLT NECK NJ 07722
John Neis	director	505 S. ROSA ROAD, SUITE 201, MADISON WI 53719
Stefan Loren	director	3226 AVENIDA DE SUENO, CARLSBAD CA 92009
Stephen A Hill	director	50 AVENUE GENERAL DE GAULLE, BRUXELLES C9 9999999999
Igor D Grachev	officer: Chief Medical Officer	15 REID LANE, MILLSTONE TWP NJ 08535
Bernhardt Charles Thomas Iii	officer: Interim CFO	23 BIRCH ROAD, MALVERN PA 19355